As we’ve covered in previous posts and in the IPR section of this blog, several IPR petitions have been filed against patents relating to the biologic products Humira (adalimumab) and Rituxan (rituximab).
The PTAB has now issued decisions on whether it will institute IPR on the three Rituxan (rituximab) IPR petitions filed by Boehringer Ingelheim: IPR was instituted for IPR2015-00417 (U.S. Patent No. 7,976,838) and IPR 2015-00415 (U.S. Patent No. 7,820,161). IPR was not instituted for IPR2015-00418 (U.S. Patent No. 8,329,172).
We will continue to track these proceedings and other biosimilar-related IPR activity here at the Big Molecule Watch. For an updated collection of relevant IPR documents, check out the IPR section under “Links” to the right of this page.